Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.404 Factor de Impacto de 5 años: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v30.i3.10
pages 223-237

Development of Safe and Effcacious Viral Vaccines for Animals

Tilahun Yilma
International Laboratory of Molecular Biology for Tropical Disease Agents, School of Veterinary Medicine, and Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California
Paulo Verardi
Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, Connecticut
Leslie Jones
International Laboratory of Molecular Biology for Tropical Disease Agents, School of Veterinary Medicine, University of California, Davis, California


We have taken a number of approaches to improve the safety and efficacy of recombinant vaccines for use in humans and animals, including: choice of the strain of vaccinia virus (VACV) used as a vector, insertional inactivation of virulence and immunoregulatory genes of VACV, and expression of cytokine genes that attenuate the vector by more than a million-fold without reduction in immunogenicity. These strategies are illustrated by providing examples of recombinant VACV (rVACV) vaccines we have developed for rinderpest, vesicular stomatitis, simian immunodeficiency virus, and smallpox. We constructed rVACVs expressing interferon-gamma (IFN -γ) and lacking the immune-modulating genes B8R, B13R, and B22R. IFN-γ is a cytokine with potent immunoregulatory, antineoplastic, and antiviral properties. These rVACVs replicated to high titers in tissue culture, yet were avirulent in both immunocompromised and immunocompetent mice with no detectable viral replication in these animals. A single immunization elicited potent humoral, T-helper, and cytotoxic T-cell immune responses in mice despite the absence of any detectable virus replication in vivo. IFN-γ co-expression and the inactivation of one or more VACV immune-modulating genes provide an optimized method for increasing the safety while maintaining the efficacy of rVACV vaccines for use in humans and animals.

Articles with similar content:

Genetic Requirements for the Development and Differentiation of lnterleukin-17-Producing γδ T Cells
Critical Reviews™ in Immunology, Vol.32, 2012, issue 1
Sandra M. Hayes, Renee M. Laird
DNA Vaccines
Critical Reviews™ in Immunology, Vol.18, 1998, issue 5
Wayne C. Lai, Michael Bennett
Expression and Function of Fc Receptors in the Thymus
Critical Reviews™ in Immunology, Vol.15, 1995, issue 3-4
Georges Leclercq , Jean Plum
Immunotherapeutic Treatment of Autoimmune Diabetes
Critical Reviews™ in Immunology, Vol.33, 2013, issue 3
Jae Hyeon Kim, Hun Sik Kim, Sang-Man Jin, Myung-Shik Lee, Kyoung-Ah Kim
Long-Acting Injectables: Current Perspectives and Future Promise
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 2
Komal Chaudhary, Mayur M. Patel, Priti J. Mehta